T. Rowe Price Associates
AKCA

T. Rowe Price Associates’s Akcea Therapeutics Inc AKCA Stock Holding History

T. Rowe Price Associates’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-955,568
Closed -$26.4M – 2637
2017
Q3 		$26.4M Buy
+955,568
New +$17.7M ﹤0.01% 1082

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

T. Rowe Price Associates's AKCA Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Akcea Therapeutics Inc (AKCA) in Q4 2017, closing a stake of 955,568 shares — an estimated $26.4M sold.

T. Rowe Price Associates first reported a position in AKCA in Q3 2017 and held it in 1 quarter. The position peaked at $26.4M in Q3 2017. 58 funds tracked by Wall St. Rank hold AKCA as of Q4 2017.

  • T. Rowe Price Associates reported no remaining Akcea Therapeutics Inc position as of Q4 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 955,568 Akcea Therapeutics Inc shares in Q4 2017, an estimated $26.4M.
  • T. Rowe Price Associates first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 1 quarter.
  • T. Rowe Price Associates's Akcea Therapeutics Inc position peaked at $26.4M in Q3 2017.
  • 58 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.